Pfizer Inc. and Teva Pharmaceutical Industries Ltd. have reached a settlement to resolve patent litigation related to Teva's generic version of Pfizer's Viagra erectile dysfunction tablets.


Pfizer, Teva, Viagra, patenti litigation, generic version, Viagra generic, erectile dysfunction, sildenafil citrate


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Pfizer, Teva settle Viagra patent litigation

December 17th, 2013

NEW YORK and JERUSALEM – Pfizer Inc. and Teva Pharmaceutical Industries Ltd. have reached a settlement to resolve patent litigation related to Teva's generic version of Pfizer's Viagra erectile dysfunction tablets.

The companies said Tuesday that under the agreement, Teva can launch a generic version of Viagra in the United States on Dec. 11, 2017, or earlier under certain circumstances. Teva will pay Pfizer a royalty for a license to produce its generic version. No other details of the settlement were disclosed.

The settlement relaties to Pfizer's patent covering the use of Viagra (sildenafil citrate 25-, 50- and 100-mg tablets), which expires in April 2020, including pediatric exclusivity.

Teva has received tentative approval from the Food and Drug Administration for its generic Viagra product.

Viagra had annual U.S. sales of about $1.2 billion as of September, based on IMS Health data cited by Teva.

More Supplier News Breaks >>
Advertisement